Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-23T17:07:38.376Z Has data issue: false hasContentIssue false

518 – Intermittent Theta Burst Stimulation (ITBS) for the Treatment of Negative Symptoms in Schizophrenia

Published online by Cambridge University Press:  15 April 2020

R. Bation
Affiliation:
EA 4615, Institut Fédératif des Neurosciences de Lyon, Université Lyon 1, Bron, France
J. Brunelin
Affiliation:
EA 4615, Institut Fédératif des Neurosciences de Lyon, Université Lyon 1, Bron, France
C. Damasceno
Affiliation:
EA 4615, Institut Fédératif des Neurosciences de Lyon, Université Lyon 1, Bron, France
T. D’Amato
Affiliation:
EA 4615, Institut Fédératif des Neurosciences de Lyon, Université Lyon 1, Bron, France
E. Poulet
Affiliation:
EA 4615, Institut Fédératif des Neurosciences de Lyon, Université Lyon 1, Bron, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

High frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral prefrontal cortex (DLPFC) has been shown effective for reducing persistant negative symptoms of schizophrenia. Intermittent theta burst stimulation (iTBS) is a new paradigm of rTMS that allowed more sustained facilitation effect.

Aims:

The aim of this study is to investigate the effect of theta burst in reduction of persistant negative symptoms in schizophrenia.

Methods:

24 adult schizophrenia outpatients were assigned to receive iTBSat 80% motor threshold, or sham TMS over the left DLPFC, daily; for 20 sessions. The primary outcome measure was the Scale for the Assessment of Negative Symptoms (SANS).score. Secondary outcomes included depression as measured with the Calgary Depression Scale (CDS), and cogntion as assessed with digit span and trail making test. Patients were followed-up 6 months afterwards.

Results:

The primary outcome measure (change in Scale for Assessment of Negative Symptoms score) showed a statistically significant drop at month 1, 3 and 6 for the iTBS group, but not ther placebo groups. Digit span and trail making test score were also significally improved after treatment in iTBS group. Calgary depression scale score did not demontrate any significant change.

Conclusions:

iTBS may serve as a relatively noninvasive treatment of the negative and neurocognitive deficits associated with schizophrenia.

ClinicalTrials.gov Identifier: NCT00875498

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.